GlassScriptPhysician profile
Apurv Varia
NPI 1578857512
$21,663.15
in general payments reported to CMS, 2019-2025
50 companies · $4,849 in 2025
The $4,849 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,069 · 2020: $1,073 · 2021: $1,989 · 2022: $3,376 · 2023: $3,731 · 2024: $4,575 · 2025: $4,849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $800 · Education: $52.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,302.59 |
| Consulting Fee | $800.00 |
| Education | $52.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,099.16 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,226.93 | 2019-2025 | Stelara, Tremfya, Remicade |
| Takeda Pharmaceuticals U.S.A., INC. | $1,807.20 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,448.55 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Qol Medical, LLC | $1,414.39 | 2019-2025 | Sucraid, Sucraid |
| Capsovision, INC. | $912.22 | 2024-2025 | Capsocam Colon, Capsocam Plus |
| Celgene Corporation | $833.00 | 2021-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $512.73 | 2019-2024 | Dificid, Zinplava |
| Janssen Scientific Affairs, LLC | $498.23 | 2022-2025 | Tremfya, Stelara, Remicade |
| Ferring Pharmaceuticals INC. | $406.54 | 2019-2025 | Rebyota, Clenpiq |
| Medtronic, INC. | $405.03 | 2021-2025 | Pillcam, Nexpowder |
| Braintree Laboratories, INC. | $404.28 | 2019-2025 | Suflave, Sutab |
| Romark Laboratories, Lc | $402.60 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $398.40 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $382.73 | 2022-2025 | Ibsrela |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $378.52 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $303.46 | 2019-2025 | |
| Pfizer INC. | $272.15 | 2019-2025 | |
| Madrigal Pharmaceuticals | $259.25 | 2024-2025 | Rezdiffra, Resmetirom |
| E.R. Squibb & Sons, L.L.C. | $243.48 | 2021-2022 | |
| Genzyme Corporation | $242.97 | 2024-2025 | |
| Redhill Biopharma INC. | $229.26 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $227.13 | 2020-2024 | Linzess |
| Lilly USA, LLC | $225.55 | 2024-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $199.86 | 2019-2025 | |
| Lucid Diagnostics INC. | $180.07 | 2022 | |
| Evoke Pharma, INC. | $174.77 | 2023-2024 | Gimoti |
| Vivus LLC | $171.87 | 2021-2024 | Qsymia, Pancreaze |
| Pentax of America, INC. | $155.30 | 2023 | C2 Cryoballoon |
| Nestle Healthcare Nutrition INC. | $154.53 | 2021-2023 | |
| Celltrion USA INC. | $145.17 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Aimmune Therapeutics, INC. | $141.42 | 2024-2025 | Vowst, Zenpep |
| Boston Scientific Corporation | $105.30 | 2019-2024 | Alliance II |
| Neuraxis, INC. | $77.48 | 2025 | |
| Exact Sciences Corporation | $70.19 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.57 | 2023 | Cyltezo |
| Ipsen Biopharmaceuticals, INC | $54.54 | 2025 | Iqirvo |
| Novo Nordisk INC | $53.04 | 2025 | Wegovy |
| Sandoz INC. | $49.34 | 2023 | Hyrimoz |
| Alnylam Pharmaceuticals INC. | $48.63 | 2023-2025 | Oxlumo, Givlaari |
| Ucb, INC. | $42.18 | 2019 | |
| Daiichi Sankyo INC. | $40.25 | 2019-2021 | |
| Shire North American Group INC | $36.08 | 2019 | |
| Alexion Pharmaceuticals, INC. | $34.38 | 2019 | |
| Biocon Biologics INC | $32.21 | 2024-2025 | Yesintek, Hulio |
| Alfasigma USA, INC. | $30.68 | 2020-2022 | |
| Enterra Medical, INC. | $24.48 | 2023 | |
| Amag Pharmaceuticals, INC. | $16.42 | 2021 | |
| Endo Pharmaceuticals INC. | $16.04 | 2019 | |
| Olympus America INC. | $12.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apurv Varia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.